Lupus nephritis: A review of the current pharmacological treatments

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2263-2277

  Mercadal, Lucile ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Azathioprine; Cyclophosphamide; Cyclosporin; DHEA; Hydroxychloroquine; LJP 394; Lupus nephritis; Mycophenolate mofetil; Rituximab

Indexed keywords

ABETIMUS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA ANTIBODY; DOUBLE STRANDED DNA; GONADORELIN AGONIST; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PRASTERONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; TRIPTORELIN;

ACNE; AMENORRHEA; ANTIBODY TITER; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HAIR LOSS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INFECTION RISK; INTERMETHOD COMPARISON; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MONOTHERAPY; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; PLASMAPHERESIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS;

EID: 8544253995     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2263     Document Type: Review

References (92)

1. CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. (2004) 350:971-980.
2. KOLASINSKI SL, CHUNG JB, ALBERT DA. What do we know about lupus membranous nephropathy? An analytic review. Arthritis Rheum. (2002) 47(4):450-455.
3. MERCADAL L, MONTCEL ST, NOCHY D, QUEFFEULOU G, PIETTE JC, ISNARD-BAGNIS C, TINEZ F: factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol. Dial. Transplant. (2002) 17(10):1771-1778.
4. BALOW JE, AUSTIN HA 3rd: Therapy of membranous nephropathy in systemic lupus erythematosus. Semin. Nephrol. (2003) 23 4)386-391.
5. STEINBERG AD, KALTREIDER HB, STAPLES PJ, GOETZL EJ, TALAL N, KER JL: Cyclophosphamide in lupus nephritis: a controlled trial? Ann. Intern. Med. (1971) 75:165-171.
6. STEINBERG AD, KER JL: A double-blind controlled-trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum. (1974) 17:923-937.
7. KER JL, KLIPPEL JH, PLOTZ PH, Steinberg AD: Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann. Intern. Med. (1975) 83:606-615.
8. DONADIO JV Jr, HOLLEY KE, FERGUSON RH, ILSTRUP DM: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednsione and cyclophosphamide. N. Engl. J. Med. (1978) 299: 51-1155.
9. CARETTE S, KLIPPEL JH, KER JL et al.: Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann. Intern. Med. (1983) 99:1-8.
10. DINANT HJ, KER JL, KLIPPEL JH, BALOW JE, PLOTZ PH, STEINBERG AD: Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann. Intern. Med. (1982) 6(Pt 1): 728-36
11. AUSTIN HA, KLIPPEL JH, BALOW JE et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. (1986) 314:614-619.
12. STEINBERG AD, STEINBERG SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. (1991) 34:945-950.
13. SZTEJNBOK M, STEWART A, DIAMOND H, KAPLAN D: Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. (1971)14(5):639-645.
14. CADE R, SPOONER G, SCHLEIN E et al.: Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron (1973) 10(1):37-56.
15. HAHN BH, KANTOR OS, OSTERLAND CK: Azathioprine plus prednisone compared with prednisone alone in the treatement of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann. Intern. Med. (1975) 83:597-605.
16. DONADIO JV Jr, HOLLEY KE, WAGONER RD, FERGUSON RH, MCDUFFIE FC: Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum. (1974) 17(5):573-581.
17. FELSON DT, ANDERSON J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N. Engl. J. Med. (1984) 311:1528-1533.
18. BANSAL VK, BETO JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am. J. Kidney Dis. (1997) 29 2):193-199.
19. FLANC RS, ROBERTS MA, STRIPPOLI GF, CHADBAN SJ, KERR PG, ATKINS RC: Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomised controlled trials. Am. J. Kidney Dis. 43(2):197-208.
20. LIGTENBERG G, GROOTSCHOLTEN CM, DERKSEN RHWM, BERDEN JHM: Cyclophosphamide pulse therapy versus azathioprine and methylprednisolone pulses in proliferative lupus nephritis: first results of a randomised prospective multicenter study. J. Am. Soc. Nephrol. (2002) 13: 4A.
21. GOURLEY MF, AUSTIN HA 3RD, SCOTT D et al.: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomised, controlled trial. Ann. Intern. Med. (1996 1)125(7):549-557.
22. ILLEI GG, AUSTIN HA, CRANE M et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. ( 2001 21)135(4):248-257.
23. HOUSSIAU FA, VASCONLOS C, D'CRUZ D et al.: Immunosuppressive therapy in lupus nephritis: the EURO-Lupus Nephritis Trial, a randomised trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 46:2121-2131.
24. CATHCART ES, IDELSON BA, SCHEINBERG MA, COUSER WG: Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet (1976) 1(7952 ):163-166.
25. DOSA S, CAIRNS SA, LAWLER W, MALLICK NP, SLOTKI IN: The treatment of lupus nephritis by methyl prednisolone pulse therapy. Postgrad. Med. J. (1978) 54(635):628-632.
26. LEVINSKY RJ, CAMERON JS, SOOTHILL JF: Serum immune complexes and disease activity in lupus nephritis. Lancet (1977 12) 1 8011):564-567.
27. BARRON KS, PERSON DA, BREWER EJ, BEALE MG, ROBSON AM: Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J. Pediatr. (1982) 101:137-141.
28. MOK CC, HO CT, SIU YP et al.: Treatment of diffuse proliferative lupus glomerulonephritis: comparison of two cyclophosphamide-containing regimens. Am J Kidney disease (2001) 38:256-264.
29. GLICKLICH D, ACHARYA A: Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis. (1998) 32(2):318-322.
30. DOOLEY MA, COSIO FG, NACHMAN PH et al.: Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol. (1999) 10(4):833-839.
31. GAUBITZ M, SCHORAT A, SCHOTTE H, KERN P, DOMSCHKE W: Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus (1999) 8(9):731-736.
32. BURATTI S, SZER IS, SPENCER CH, PARTOSH S, REIFF A: Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J. Rheumatol. (2001) 28: 103-2108.
33. KARIM MY, ALBA P, CUADRADO MJ et al.: Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (2002) 41:876-882.
34. CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. (2000) 343:1156-1162.
35. CHAN TM, WONG WS, LAU CS, ISANG EWK, JI YL, MOK MY et al. Prolonged follow-up of patients with diffuse proliferative lupus nephritis treated with prednisone and mycophenolate mofetil. J. Am. Soc. Nephrol. (2001) 12:A1010.
36. GINZLER EM, ARANOW C, BUYON J, DOOLEY MA, MERRILL JT, PETRI M et al.: A multicenter study of mycophenolate mofetil vs intravenous cyclophosphamide as induction therapy for severe lupus nephritis: preliminary results. American Congress Rheumatology (2003) (Abstract 1690).
37. JONES JV, CUMMING RH, BUCKNALL RC, ASPLIN CM: Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet (1976) 1(7962):709-711.
38. JONES JV: Plasmapheresis in SLE. Clin. Rheum. Dis. (1982) 8(1)243-260. F
39. SCHLANSKY R, DEHORATIUS RJ, PINCUS T, TUNG KS: Plasmapheresis in systemic lupus erythematosus: a cautionary note. Arthritis Rheum. (1981) 24(1):49-53.
40. LEWIS EJ, HUNSICKER LG, LAN SP, ROHDE RD, LACHIN JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N. Engl. J. Med. (1992) 326(21):1373-1379.
41. WALLACE DJ, GOLDFINGER D, PEPKOWITZ SH et al.: Randomised controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J. Clin. Apheresis. (1998) 13(4):163-166.
42. DANIELI MG, PALMIERI C, SALVI A, REFE MC, STRUSI AS, DANIELI G: Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J. Clin. Apheresis. (2002) 17(2):72-77
43. TRAYNOR AE, SCHROEDER J, ROSA RM et al.: Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet (2000) 356(9231):701-707.
44. PETRI M, JONES RJ, BRODSKY RA: High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. (2003) 48(1):166-173.
45. FAVRE H, MIESCHER PA, HUANG YP, CHATELANAT F, MIHATSCH MJ: Ciclosporin in the treatment of lupus nephritis. Am. J. Nephrol. (1989) 9(Suppl.1):57-60.
46. DOSTAL C, TESAR V, RYCHLIK I et al.: Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus (1998) 7 1):29-36.
47. TOKUDA M, KURATA N, MIZOGUCHI A et al.: Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum. (1994) 37(4):551-558.
48. MANGER K, KALDEN JR, MANGER B: Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br. J. Rheumatol. (1996) 35(7):669-675.
49. CACCAVO D, LAGANA B, MITTERHOFER AP et al.: Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum. (1997) 40(1):27-35.
50. TAM LS, LI EK, LEUNG CB et al.: Long-term treatment of lupus nephritis with cyclosporin A. QJM (1998) 91(8 ):573-580.
51. FU LW, YANG LY, CHEN WP, LIN CY: Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br. J. Rheumatol. (1998) 37(2):217-221.
52. ILLEI GG, TAKADA K, PARKIN D et al.: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomised controlled studies. Arthritis Rheum. (2002) 46(4):995-1002.
53. MOK CC, HO CT, CHAN KW, LAU CS, WONG RW: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. (2002) 46(4):1003-1013.
54. BOUMPAS DT, AUSTIN HA 3rd, VAUGHN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 340 8822):741-745.
55. TER BORG EJ, HORST G, HUMMEL EJ, LIMBURG PC, KALLENBERG CG: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. (1990) 33 5):634-643.
56. SWAAK AJ, GROENWOLD J, BRONSVELD, W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann. Rheum. Dis. (1986) 45(5):359-366.
57. PETRI M, GE ESE M, ENGLE E, HOCHBERG M: Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. (1991) 34(8):937-944.
58. ESDAILE JM, ABRAHAMOWICZ M, JOSEPH L, MACKENZIE T, LI Y, DANOFF D: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum. (1996) 39(3):370-378.
59. HO A, MAGDER LS, BARK SG, PETRI M: reases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. (2001) 44(10):2342-2349.
60. BOOTSMA H, SPRONK P, DERKSEN R et al.: Prevention of relapses in systemic lupus erythematosus. Lancet (1995) 345 8965):1595-1599.
61. BIJL M, HORST G, BOOTSMA H, LIMBURG PC, KALLENBERG CG: Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann. Rheum. Dis. (2003) 62 6):534-539.
62. PAGE F: Treatment of lupus crythematosus with mepacrine. Lancet (1951 27) 2(17):755-758.
63. RYNES RI, KROHEL G, FALBO A, REINECKE RD, WOLFE B, BARTHOLOMEW LE: Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum. (1979) 22(8):832-836.
64. SPALTON DJ, VERDON ROE GM, HUGHES GR: Hydroxychloroquine, dosage parameters and retinopathy. Lupus (1993) 2(6 ):355-358.
65. RUDNICKI RD, GRESHAM GE, ROTHFIELD NF: The efficacy of antimalarials in systemic lupus erythematosus. J. Rheumatol. (1975) 2(3):323-330.
66. NO AUTHORS LISTED: A randomised study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. (1991) 324(3):150-154.
67. MEINAO IM, SATO EI, ANDRADE LE, FERRAZ MB, ATRA E: Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus (1996) 5(3)237-241.
68. SUZUKI T, SUZUKI N, ENGLEMAN EG, MIZUSHIMA Y, SAKANE T: Low serum levels of dehydroepiandrosterone cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. (1995) 99(2):251-255.
69. MENO-TETANG GM, BLUM RA, SCHWARTZ KE, JUSKO WJ: Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. J. Clin. Pharmacol. (2001) 41(11):1195-1205.
70. LAHITA RG, BRADLOW HL, GINZLER E, PANG S, NEW M: Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. (1987) 30(3):241-248.
71. VAN VOLLENHOVEN RF, ENGLEMAN EG, MCGUIRE JL: An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. (1994) 37(9):1305-1310.
72. VAN VOLLENHOVEN RF, ENGLEMAN EG, MCGUIRE JL: Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, Placebo-controlled, randomised clinical trial. Arthritis Rheum. (1995) 38(12):1826-1831.
73. CHANG DM, LAN JL, LIN HY, LUO SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomised, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46(11):2924-2927.
74. PETRI MA, LAHITA RG, VAN VOLLENHOVEN RF et al., and the GL601 STUDY GROUP: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomised, placebo-controlled trial. Arthritis Rheum. (2002) 46 7):1820-1829.
75. MOK CC, LAU CS, WONG RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. (1998) 41(5):831-837.
76. WANG CL, WANG F. BOSCO JJ: Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus (1995) 4(1):11-14.
77. IOANNIDIS JP, KATSIFIS GE, TZIOUFAS AG, MOUTSOPOULOS HM: Predictors of sustained amenorrhoea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J. Rheumatol. (2002) 29(10):2129-2135.
78. BLUMENFELD Z, SHAPIRO D, SHTEINBERG M, AVIVI I, NAHIR M: Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus (2000) 9(6):401-405.
79. BLUMENFELD Z, HAIM N: Prevention of gonadal damage during cytotoxic therapy. Ann. Med. (1997) 29(3):199-206.
80. DAVIS JC Jr, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (I-131) in patients with systemic lupus erythematosus. J Rheumatol. (2001) 28(1):95-101.
81. BOUMPAS DT, FURIE R, MANZI S et al., and the BG9588 LUPUS NEPHRITIS TRIAL GROUP: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and reases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. (2003) 48(3):719-727.
82. SIDIROPOULOS PI, BOUMPAS DT: Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus (2004) 13(5):391-397.
83. LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG D: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46(10):2673-2677.
84. WEIDE R, HEYMANNS J, PANDORF A, KOPPLER H: Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus (2003) 12(10):779-782.
85. FRA GP, AVANZI GC, BARTOLI E: Remission of refractory lupus nephritis with a protocol including rituximab. Lupus (2003) 12 10):783-787.
86. SAITO K, NAWATA M, NAKAYAMADA S et al.: Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus (2003) 12 10):798-800.
87. LOONEY RJ, ANOLIK JH, CAMPBELL D, FELGAR RE, YOUNG F, AREND LJ et al.: B cell depletion as a e1 treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50(8):2580-2589.
88. FURIE RA, CASH JM, CRONIN ME et al.: Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. (2001) 28(2):257-265.
89. ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al., and the LJP 394 INVESTIGATOR CONSORTIUM: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomised, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 48(2):442-454.
90. DECKER JL, KLIPPEL JH, PLOTZ PH, STEINBERG AD: Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann. Int. Med. (1975) 83:606-615.
91. GINZLER E, DIAMOND H, GUTTADAURIA M, KAPLAN D: Prednisone and azathioprine compared to prednsisone plus low dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum. (1976) 19(4):693-699.
92. HU W, LIU Z, CHEN H et al.: Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin. Med. J. (2002) 115(5):705-709.